Merck, Inc.
🇵🇭Philippines
Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease
Phase 3
Completed
- Conditions
- Dry Eye Disease
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 640
- Registration Number
- NCT00403975
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease
Phase 3
Completed
- Conditions
- Dry Eye Disease
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 500
- Registration Number
- NCT00404131
ProQuad® Intramuscular vs Subcutaneous
Phase 3
Completed
- Conditions
- RubellaMeaslesMumpsVaricella
- Interventions
- Biological: ProQuad®
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 405
- Registration Number
- NCT00402831
The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)
Phase 2
Terminated
- Conditions
- Middle Cerebral Artery Stroke
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2015-07-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 150
- Registration Number
- NCT00401310
Upper GI Handling of Branded vs. Generic Alendronate
Phase 3
Completed
- Conditions
- Osteoporosis
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2006-11-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 25
- Registration Number
- NCT00400530
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
Phase 2
Completed
- Conditions
- Breast CancerMetastatic Bone Disease
- Interventions
- First Posted Date
- 2006-11-15
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 43
- Registration Number
- NCT00399802
To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)
Phase 3
Completed
- Conditions
- Sepsis
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00397956
To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)
Phase 3
Completed
- Conditions
- InfectionPneumoniaUrinary Tract Infection
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00398099
Initial Combination With Pioglitazone Study (0431-064)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: sitagliptin 100 mg q.d./pioglitazone 30 mg q.d
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 520
- Registration Number
- NCT00397631
A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)
Phase 2
Terminated
- Conditions
- Osteoarthritis
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2
- Registration Number
- NCT00397683
- Locations
- 🇲🇽
Merck Sharp & Dohme De Mexico, S.A. De C.V., Mexico, D.f., Mexico
🇺🇸Call for Information, Perkasie, Pennsylvania, United States
🇵🇱MSD Polska Sp. z o.o. Dzial Medyczny, Warszawa, Poland
© Copyright 2025. All Rights Reserved by MedPath